PRGO · PERRIGO Co plc
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 5, 2026TL;DR. Perrigo reported Q2 sales declines (Core net sales down 3.1%) and lower adjusted EPS, but reaffirmed its full-year 2026 outlook, completed the $359M Dermacosmetics divestiture to reduce debt, and continued gaining market share (50 bps in U.S. and Europe) despite soft category trends.
- + Reaffirmed full-year 2026 outlook despite weak quarter
- + Completed $359M Dermacosmetics divestiture with proceeds applied to debt reduction
- + Continued market share gains of 50 bps in both U.S. and Europe despite category declines
- + Infant Formula delivered 23% sales growth and ~$60M operating income improvement
- − Core net sales declined 3.1% and adjusted EPS fell 20.7% year-over-year
- − Core adjusted gross margin declined 250 bps and operating margin fell 160 bps
- − Earnings beat driven by one-time benefits not expected to recur
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PRGO
this stock
PERRIGO Co plc
|
$2.14B | +6.0% | -2.8% | — | 16.3% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.23B | +16.7% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$46.00B | -4.5% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.67B | +26.9% | +4.3% | 64.3 | 2.7% |
|
HLN
Haleon plc
|
$40.72B | -11.0% | — | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PRGO | +6.7% | +2.3% | +39.3% | +0.8% | +6.0% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +7.3% | +2.2% | +27.1% | +1.4% | -5.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.